Indirect comparison meta-analysis of aspirin therapy after coronary surgery.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 14656836.
- Also identified by PMC identifier 286307.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the efficacy of low and medium dose aspirin therapy after coronary surgery by using an indirect comparison meta-analysis. Systematic literature search of Medline, Embase, Cochrane controlled trials register, and trial register sites on the internet. Outcome was evaluated by angiography and reported as graft occlusion and rate of events in patients. Trials that did not include aspirin as the sole therapy or did not have a placebo control arm were excluded. Articles were assessed for eligibility and quality and grouped according to dosage. The estimated difference in effect of low and medium dose aspirin on graft occlusion was obtained by combining the estimated log relative risks of low dose with placebo and medium dose with placebo. For graft occlusion, the medium dose trials yielded a relative risk reduction of 45% compared with 26% for the low dose trials. The greater effect in the medium dose trials is summarised by a relative risk ratio of 0.74 (95% confidence interval 0.52 to 1.06; P = 0.10) for graft occlusion and 0.81 (0.57 to 1.16; P = 0.25) for events in patients. Medium dose aspirin may more successfully reduce graft occlusion than low dose regimens within the first year after coronary surgery.
Medical subject headings
- Aspirin
- Blood Vessel Prosthesis Implantation
- Coronary Disease
- Graft Occlusion, Vascular
- Platelet Aggregation Inhibitors